Jiangsu Aidea Pharmaceutical Co., Ltd. (Aidea Pharma, 688488.SH) was established in 2009 and listed on the Shanghai Stock Exchange STAR Market in 2020. As a high-tech pharmaceutical company, Aidea Pharma focuses on the development of anti-HIV/AIDS product portfolio while leveraging its competitive advantages in the field of human urinary proteins production.

A pioneer in R&D of anti-HIV/AIDS products in China, with two innovative drugs successfully approved for marketing

A leading manufacturer of human urinary protein products in China, with five products recognized as provincial high-tech products

A company dedicated to exploring innovative medicines, serving unmet clinical needs worldwide with its unique expertise and professional talents